An unexpected ally in heart failure treatment: Unlocking the potential of sodium‐glucose cotransporter 2 inhibitors across patient subpopulations

Bibliographic Details
Main Authors:	Sander Trenson, Mateusz Sokolski
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	ESC Heart Failure
Online Access:	https://doi.org/10.1002/ehf2.15167
Tags:	Add Tag No Tags, Be the first to tag this record!

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

Effect of sodium-glucose cotransporter 2 inhibitors on ventricular function in systemic right ventricular failure
by: Lorna Swan, et al.
Published: (2025-07-01)

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond
by: Zein Alabdin Hannouneh, et al.
Published: (2025-01-01)

Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
by: Nicia I. Profili, et al.
Published: (2025-03-01)

Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
by: Miloud Cherbi, et al.
Published: (2025-04-01)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
by: Mauro Gori, et al.
Published: (2022-07-01)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
by: Brent Deschaine, et al.
Published: (2022-06-01)

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01)

Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor
by: D. A. Lebedev, et al.
Published: (2020-10-01)

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
by: Ashot A. Avagimyan, et al.
Published: (2025-02-01)

Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now
by: Alessandro Cuttone, et al.
Published: (2025-05-01)

Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
by: Tapan A. Patel, et al.
Published: (2025-03-01)

Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Post-Transurethral Resection of Bladder Tumor Infection and Prognosis
by: Nobutaka Nishimura, et al.
Published: (2025-07-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
by: E. V. Kovalenko, et al.
Published: (2021-02-01)

The effect of sodium-glucose cotransporter 2 inhibition mediated by blood metabolites in lymphocytic leukemia
by: Diguang Wen, et al.
Published: (2025-11-01)

Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study
by: Tao Liu, et al.
Published: (2025-08-01)

A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin
by: Shoko Sahara, et al.
Published: (2025-08-01)

Gender Bias in Clinical Trials of Sodium–Glucose Cotransporter 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review
by: Santiago José Lora-Escobar, et al.
Published: (2025-01-01)

Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy
by: Maharan Kabha, et al.
Published: (2025-07-01)

Efficacy and Safety of Bexagliflozin, a Selective Sodium-Glucose Cotransporter-2 Inhibitor, in Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: A.B.M. Kamrul-Hasan, et al.
Published: (2025-01-01)

Genetic deletion of the sodium phosphate cotransporter NaPi2a ameliorates heart failure in mice
by: Hiroko Yamauchi-Sawada, et al.
Published: (2025-08-01)

Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors
by: L. V. Kremneva, et al.
Published: (2023-12-01)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
by: Michishige Terasaki, et al.
Published: (2017-01-01)

Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study
by: XiaoYue Qin, et al.
Published: (2025-05-01)

Sodium–glucose cotransporter 2 inhibitors ameliorate glutathione cysteine ligase modifier-mediated oxidative stress and subsequent ferroptosis in proximal tubules of diabetic kidney disease
by: Yi-Chun Tsai, et al.
Published: (2025-12-01)

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
by: Moritake Iguchi, et al.
Published: (2023-06-01)

A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
by: D. P. Golubovskaya, et al.
Published: (2022-11-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes
by: Koichi Yabiku, et al.
Published: (2020-01-01)

Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis
by: Yao Wang, et al.
Published: (2025-08-01)

Risk of severe lower extremity arterial disease in elderly Japanese patients with type 2 diabetes: a propensity score-matched model analysis of sodium-glucose cotransporter 2 inhibitors versus metformin
by: Takeshi Horii, et al.
Published: (2025-07-01)

WCN25-1188 THE USEFULNESS OF URINARY N-ACETYL- β-D-GLUCOSAMINIDASE-CREATININE RATIO AS THE BIOMARKER TO DECIDE LONG-TERM USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR IN DIABETIC KIDNEY DISEASE
by: Jonghwan Jung, et al.
Published: (2025-02-01)

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan
by: A. Kashiwagi, et al.
Published: (2023-05-01)

Continuation Versus Discontinuation of Sodium‐Glucose Cotransporter‐2 Inhibitors and Cardiorenal Outcomes Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Cohort Study With a Target Trial Emulation Framework
by: Yaa‐Hui Dong, et al.
Published: (2025-08-01)

Study protocol of the multicentre, randomised, triple-blind, placebo-controlled MERCURI-2 trial: promoting effective renoprotection in cardiac surgery patients by inhibition of sodium glucose cotransporter (SGLT)-2
by: Frederique Paulus, et al.
Published: (2025-05-01)

Challenging the Restrictive Approach: Reconsidering Sodium-Glucose Transport Protein 2 Inhibitor Use in CKD
by: Ozant Helvaci, et al.
Published: (2024-06-01)

The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats
by: Seyhmus Tan, et al.
Published: (2025-06-01)

Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect
by: O N. Kurochkina, et al.
Published: (2024-06-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

An unexpected ally in heart failure treatment: Unlocking the potential of sodium‐glucose cotransporter 2 inhibitors across patient subpopulations

Similar Items

Similar Items